Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

The bounc­er is let­ting a pre­clin­i­cal biotech en­ter the IPO club Thurs­day night.

Yes, the time­stamp is 2024. A pre­clin­i­cal Nas­daq of­fer­ing sounds like a 2020 or 2021 head­line, but Cal­i­for­nia start­up Metageno­mi is bet­ting that it can op­er­ate in the pub­lic are­na for mul­ti­ple quar­ters, per­haps a few years, be­fore even test­ing its gene edit­ing tools in hu­mans.

Metageno­mi’s risk-tak­ing comes in the form of a $93.7 mil­lion IPO, priced at $15 per share $MGX, the low end of the range it pro­posed ear­li­er this week. The biotech’s last pri­vate round was a $100 mil­lion Se­ries B ex­ten­sion dis­closed in Jan­u­ary 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA